Rheumatology

300.3K Papers

Follow See full results

Article Rheumatology

Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study

Roy Fleischmann, Eduardo Mysler, Louis Bessette, Charles G. Peterfy, Patrick Durez, Yoshiya Tanaka, Jerzy Swierkot, Nasser Khan, Xianwei Bu, Yihan Li, In-Ho Song

Summary: This study assessed the long-term safety and efficacy of the Janus kinase inhibitor upadacitinib compared to adalimumab in patients with active rheumatoid arthritis. The results showed that upadacitinib had numerically better clinical responses than adalimumab over a period of 3 years, and the adverse event rates were generally comparable between the two drugs, although certain adverse events were reported at higher rates with upadacitinib.

RMD OPEN (2022)

添加到收藏夹

Review Rheumatology

One year in review 2022: systemic lupus erythematosus

D. Zucchi, E. Elefante, D. Schiliro, V. Signorini, F. Trentin, A. Bortoluzzi, C. Tani

Summary: This review summarizes the most relevant data on systemic lupus erythematosus (SLE) emerged in 2021, including pathogenetic pathways, biomarkers, and clinical manifestations. The emerging insights and new therapeutic strategies provide potential improvements in the control of SLE.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY (2022)

添加到收藏夹

Article Rheumatology

Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial

Maria C. Cid, Sebastian H. Unizony, Daniel Blockmans, Elisabeth Brouwer, Lorenzo Dagna, Bhaskar Dasgupta, Bernhard Hellmich, Eamonn Molloy, Carlo Salvarani, Bruce C. Trapnell, Kenneth J. Warrington, Ian Wicks, Manoj Samant, Teresa Zhou, Lara Pupim, John F. Paolini

Summary: This study evaluated the efficacy of the GM-CSF receptor antagonist mavrilimumab in maintaining disease remission in patients with giant cell arteritis. The results showed that mavrilimumab plus prednisone was superior to placebo plus prednisone in terms of time to flare and sustained remission.

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Review Orthopedics

Osteoarthritis year in review 2021: biology

Y. Jiang

Summary: This review on osteoarthritis biology summarizes a series of research articles published between the 2020 and 2021 Osteoarthritis Research Society International (OARSI) World Congress. It focuses on the new discoveries of osteoarthritis's cellular molecular mechanism, anatomical signatures, potential therapeutic targets, and regenerative therapy. The review highlights the recently developed potential therapeutic targets, such as TGF13 and Wnt signaling, and discusses their roles in joint tissue homeostasis, joint aging, and cartilage homeostasis. It also introduces new anatomical structures and osteoarthritis features and discusses the possibility of tissue regeneration in osteoarthritis joints. Lastly, it discusses the clinical evidence of the importance of delivery site of bone marrow stem cells for osteoarthritis treatment.

OSTEOARTHRITIS AND CARTILAGE (2022)

添加到收藏夹

Review Rheumatology

Psoriatic arthritis from a mechanistic perspective

Georg Schett, Proton Rahman, Christopher Ritchlin, Iain B. McInnes, Dirk Elewaut, Jose U. Scher

Summary: This article discusses a comprehensive mechanistic concept of psoriatic arthritis, including the genetic, biomechanical, metabolic, and microbial factors that contribute to the development of the disease and its manifestations and consequences.

NATURE REVIEWS RHEUMATOLOGY (2022)

添加到收藏夹

Article Rheumatology

Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial

Carlo Scognamiglio Renner Araujo, Ana Cristina Medeiros-Ribeiro, Carla G. S. Saad, Karina Rossi Bonfiglioli, Diogo Souza Domiciano, Andrea Yukie Shimabuco, Matheus Santos Rodrigues Silva, Emily Figueiredo Neves Yuki, Sandra Gofinet Pasoto, Tatiana Pedrosa, Leonard de Vinci Kanda Kupa, Gioanna Zou, Rosa M. R. Pereira, Clovis Artur Silva, Nadia Emi Aikawa, Eloisa Bonfa

Summary: This study evaluated the effect of discontinuing methotrexate (MTX) for 2 weeks after each dose of the Sinovac-CoronaVac vaccine on immunogenicity and safety in patients with rheumatoid arthritis (RA). The results showed that the group that discontinued MTX had a higher rate of seroconversion and higher antibody titers compared to the group that continued MTX. However, there was an increased risk of flare after the second MTX withdrawal.

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Article Rheumatology

American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4

Jeffrey R. Curtis, Sindhu R. Johnson, Donald D. Anthony, Reuben J. Arasaratnam, Lindsey R. Baden, Anne R. Bass, Cassandra Calabrese, Ellen M. Gravallese, Rafael Harpaz, Andrew Kroger, Rebecca E. Sadun, Amy S. Turner, Eleanor Anderson Williams, Ted R. Mikuls

Summary: This study aims to provide guidance for rheumatology providers on the use of COVID-19 vaccines in patients with rheumatic and musculoskeletal diseases. By summarizing the available literature and data, the study offers recommendations on vaccine efficacy, safety, and the use of immunomodulatory therapies during vaccination.

ARTHRITIS & RHEUMATOLOGY (2022)

添加到收藏夹

Article Rheumatology

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)

Laura C. Coates, Laure Gossec, Elke Theander, Paul Bergmans, Marlies Neuhold, Chetan S. Karyekar, May Shawi, Wim Noel, Georg Schett, Iain B. McInnes

Summary: The study demonstrated that guselkumab significantly improved joint and skin manifestations as well as physical function in patients with TNFi-IR PsA. A higher proportion of patients in the guselkumab group achieved ACR20 and other key secondary endpoints compared to the placebo group, with 58% of ACR20 response in the guselkumab group at week 48.

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Editorial Material Rheumatology

Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab

Renaud Felten, Floriane Gallais, Cedric Schleiss, Emmanuel Chatelus, Rose-Marie Javier, Luc Pijnenburg, Christelle Sordet, Jean Sibilia, Laurent Arnaud, Samira Fafi-Kremer, Jacques-Eric Gottenberg

LANCET RHEUMATOLOGY (2022)

添加到收藏夹

Article Rheumatology

Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles

Vivian E. Saper, Michael J. Ombrello, Adriana H. Tremoulet, Gonzalo Montero-Martin, Sampath Prahalad, Scott Canna, Chisato Shimizu, Gail Deutsch, Serena Y. Tan, Elaine F. Remmers, Dimitri Monos, Timothy Hahn, Omkar K. Phadke, Elaine Cassidy, Ian Ferguson, Vamsee Mallajosyula, Jianpeng Xu, Jaime S. Rosa Duque, Gilbert T. Chua, Debopam Ghosh, Ann Marie Szymanski, Danielle Rubin, Jane C. Burns, Lu Tian, Marcelo A. Fernandez-Vina, Elizabeth D. Mellins, Jill A. Hollenbach

Summary: Drug reaction with eosinophilia and systemic symptoms (DRESS) can occur in Still's disease patients treated with IL-1/IL-6 inhibitors, with features such as eosinophilia, liver enzyme elevation, and persistent rash. HLA-DRB1*15 haplotypes are significantly enriched in Still's disease with DRESS. Pre-prescription HLA typing and vigilance for serious reactions to these drugs are recommended.

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Article Rheumatology

Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases

Charalampos Papagoras, George E. Fragoulis, Nikoleta Zioga, Theodora Simopoulou, Kleopatra Deftereou, Eleni Kalavri, Evangelia Zampeli, Nafsika Gerolymatou, Evangelia Kataxaki, Konstantinos Melissaropoulos, Stylianos Panopoulos, Kalliopi Fragiadaki, Gerasimos Evangelatos, Vasiliki-Kalliopi Bournia, Aikaterini Arida, Anastasios Karamanakos, Maria Pappa, Alexandros Panagiotopoulos, Christos Koutsianas, Georgia Mparouta, Theodoros Dimitroulas, Stamatis-Nick Liossis, Maria G. Tektonidou, Evrydiki Kravvariti, Nikolaos Kougkas, Panagiotis Georgiou, Paraskevi Voulgari, Antonia Elezoglou, Dimitrios P. Bogdanos, Dimitrios Vassilopoulos, Petros P. Sfikakis

Summary: Vaccinated patients with systemic rheumatic diseases who experience breakthrough COVID-19 have better outcomes compared to unvaccinated patients with similar disease characteristics. This highlights the importance of COVID-19 vaccination in vulnerable populations like those with SRDs.

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Article Rheumatology

Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease

David Simon, Koray Tascilar, Filippo Fagni, Katja Schmidt, Gerhard Kroeneke, Arnd Kleyer, Andreas Ramming, Verena Schoenau, Daniela Bohr, Johannes Knitza, Thomas Harrer, Karin Manger, Bernhard Manger, Georg Schett

Summary: The study found that a third vaccination in IMID patients who did not respond to standard vaccination can induce protective immunity. Seroconversion and neutralising activity were higher in non-RTX patients compared to RTX-treated patients. T cell responses did not significantly impact vaccination efficacy.

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Article Rheumatology

Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases

Jerome Hadjadj, Delphine Planas, Amani Ouedrani, Solene Buffier, Laure Delage, Yann Nguyen, Timothee Bruel, Marie-Claude Stolzenberg, Isabelle Staropoli, Natalia Ermak, Laure Macraigne, Caroline Morbieu, Soledad Henriquez, David Veyer, Helene Pere, Marion Casadevall, Luc Mouthon, Frederic Rieux-Laucat, Lucienne Chatenoud, Olivier Schwartz, Benjamin Terrier

Summary: This study evaluated the immune responses in immunocompromised patients with systemic inflammatory diseases after receiving BNT162b2 vaccine, finding that rituximab and methotrexate had different impacts on the vaccine's immunogenicity, with the Delta variant fully escaping the humoral response in individuals treated with rituximab. Efforts to improve the immunogenicity of BNT162b2 in immunocompromised individuals are supported by these findings.

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Article Rheumatology

2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis

Cristina Ponte, Peter C. Grayson, Joanna C. Robson, Ravi Suppiah, Katherine Bates Gribbons, Andrew Judge, Anthea Craven, Sara Khalid, Andrew Hutchings, Richard A. Watts, Peter A. Merkel, Raashid A. Luqmani, DCVAS Study Grp

Summary: The study aimed to develop and validate updated classification criteria for giant cell arteritis (GCA). Through the collection of data from patients worldwide, a set of criteria for GCA classification was established and showed high sensitivity and specificity in the validation data set.

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Letter Rheumatology

Safety and disease flare of autoimmune inflammatory rheumatic diseases: a large real-world survey on inactivated COVID-19 vaccines

Yong Fan, Yan Geng, Yu Wang, Xuerong Deng, Guangtao Li, Juan Zhao, Lanlan Ji, Xiaohui Zhang, Zhibo Song, Haoze Zhang, Xiaoying Sun, Dai Gao, Wenhui Xie, Hong Huang, YanJie Hao, Zhuoli Zhang

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Review Rheumatology

Treatment of axial spondyloarthritis: an update

Abhijeet Danve, Atul Deodhar

Summary: This review summarizes the progress in the pharmacological management of axial spondyloarthritis (axSpA), including newly approved biologic DMARDs. With advances in the understanding of the immunopathogenesis of this disease, new therapies have become available, which can substantially improve symptoms, signs and quality of life.

NATURE REVIEWS RHEUMATOLOGY (2022)

添加到收藏夹

Article Rheumatology

Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study

Xiufang Kong, Ying Sun, Xiaojuan Dai, Li Wang, Zongfei Ji, Huiyong Chen, Xuejuan Jin, Lili Ma, Lindi Jiang

Summary: The study showed that TOF was superior to MTX in inducing complete remission, preventing relapse, and reducing the dose of glucocorticoids in TAK treatment. There were no significant differences in disease progression or imaging between the two groups, and TOF demonstrated a good safety profile.

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Article Rheumatology

Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial

Maarten Boers, Linda Hartman, Daniela Opris-Belinski, Reinhard Bos, Marc R. Kok, Jose A. P. Da Silva, Eduard N. Griep, Ruth Klaasen, Cornelia F. Allaart, Paul Baudoin, Hennie G. Raterman, Zoltan Szekanecz, Frank Buttgereit, Pavol Masaryk, L. Thomas Klausch, Sabrina Paolino, Annemarie M. Schilder, Willem F. Lems, Maurizio Cutolo

Summary: This study compared the effects and side effects of low-dose prednisolone and placebo treatment in elderly patients with active rheumatoid arthritis. The results showed that low-dose prednisolone can reduce disease activity and joint damage, but the side effects also increased by 24%.

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Review Rheumatology

ANCA-associated vasculitis following ChAdOx1 nCoV19 vaccination: case-based review

Arun Prabhahar, G. S. R. S. N. K. Naidu, Prabhat Chauhan, Aravind Sekar, Aman Sharma, Alok Sharma, Asheesh Kumar, Ritambhra Nada, Manish Rathi, Harbir Singh Kohli, Raja Ramachandran

Summary: Vaccination against COVID-19 may lead to an increase in autoimmune diseases, although the causality between most side effects and the vaccines remains debatable. This article reports a case of vasculitis developing 2 weeks after COVID-19 vaccination and provides a comprehensive review of clinical manifestations and treatment response of vaccine-associated vasculitis.

RHEUMATOLOGY INTERNATIONAL (2022)

添加到收藏夹

Article Rheumatology

The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology Points to Consider for Diagnosis and Management of Autoinflammatory Type I Interferonopathies: CANDLE/PRAAS, SAVI, and AGS

Kader Cetin Gedik, Lovro Lamot, Micol Romano, Erkan Demirkaya, David Piskin, Sofia Torreggiani, Laura A. Adang, Thais Armangue, Kathe Barchus, Devon R. Cordova, Yanick J. Crow, Russell C. Dale, Karen L. Durrant, Despina Eleftheriou, Elisa M. Fazzi, Marco Gattorno, Francesco Gavazzi, Eric P. Hanson, Min Ae Lee-Kirsch, Gina A. Montealegre Sanchez, Benedicte Neven, Simona Orcesi, Seza Ozen, M. Cecilia Poli, Elliot Schumacher, Davide Tonduti, Katsiaryna Uss, Daniel Aletaha, Brian M. Feldman, Adeline Vanderver, Paul A. Brogan, Raphaela Goldbach-Mansky

Summary: This study aims to improve the diagnosis, treatment, and long-term monitoring of patients with autoinflammatory interferonopathies, CANDLE/PRAAS, SAVI, and AGS. The research team developed guidelines and considerations to enhance care quality and disease outcomes.

ARTHRITIS & RHEUMATOLOGY (2022)

添加到收藏夹

«
1
2
3
4
5
»

See full results

Related Categories

Anesthesiology (212.5K) Audiology & Speech-Language Pathology (1.7K) Clinical Neurology (1.3M) Critical Care Medicine (338.4K) Dentistry, Oral Surgery & Medicine (340.8K) Dermatology (413.6K) Emergency Medicine (142.9K) Endocrinology & Metabolism (751.7K) Gastroenterology & Hepatology (856.4K) Geriatrics & Gerontology (226.3K) Gerontology (158.2K) Health Care Sciences & Services (433.8K) Hematology (653.3K) Immunology (896.7K) Infectious Diseases (453.2K) Integrative & Complementary Medicine (99.8K) Medical Ethics (26.6K) Medical Informatics (100.5K) Medical Laboratory Technology (108K) Medicine, General & Internal (1.3M) Medicine, Legal (48.4K) Medicine, Research & Experimental (710K) Nursing (297.8K) Obstetrics & Gynecology (559.8K) Oncology (1.8M) Ophthalmology (452.2K) Orthopedics (359.5K) Otorhinolaryngology (166K) Pediatrics (655.3K) Peripheral Vascular Disease (595.7K) Pharmacology & Pharmacy (1.3M) Primary Health Care (59.2K) Psychiatry (755.1K) Radiology, Nuclear Medicine & Medical Imaging (799.4K) Rehabilitation (249.2K) Surgery (1.3M) Toxicology (333.1K) Transplantation (309.7K) Tropical Medicine (112.2K) Urology & Nephrology (567K) Veterinary Sciences (455.3K)

© Peeref 2019-2024. All rights reserved.